Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Aiko Biotechnology Inc.
DescriptionCoformulation of AIKO-150, an neutral opioid antagonist, with an opioid analgesic
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationConstipation
Indication DetailsTreat opioid-induced constipation (OIC) and opioid-induced bowel dysfunction
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today